Clinical scores of study participants.

Background and purposeA proportion of individuals recovering from COVID-19 continue to experience persistent symptoms, including fatigue and cognitive difficulties — a syndrome commonly referred to as Post-COVID condition (PCC), which affects an estimated 2–10% of cases. In this study, we evaluated cerebral blood flow (CBF) to better understand the pathophysiological mechanisms underlying PCC.Materials and methodsIn this prospective, monocentric study, we analyzed clinical and cerebral blood flow (CBF) data from a cohort of 55 patients who met the WHO diagnostic criteria for Post-COVID condition (PCC) and underwent MRI approximately 11 months after a positive PCR test for SARS-CoV-2. These PCC patients were compared to a matched control group of 36 individuals who had contracted COVID-19 but did not develop PCC. CBF was assessed using arterial spin labeling (ASL), a promising non-invasive technique that provides high spatial resolution for quantifying cerebral blood flow. Additionally, we examined changes in gray matter volume and atrophy using FreeSurfer-based cortical morphometry. We further explored the relationship between regional CBF alterations and clinical symptoms, including cognitive and olfactory function, as well as fatigue.ResultsIn our cohort, 59% of PCC patients could not return to their previous level of independence or employment due to symptoms, and 81% reported fatigue on the WEIMuS questionnaire. Conventional MRI showed no evidence of cortical atrophy. While no significant differences in regional CBF emerged after FDR correction, a more explorative threshold (p ConclusionIn PCC patients, fatigue was associated with reduced perfusion in right-sided occipital regions, suggesting a potential pathophysiological basis for this symptom. These findings may also provide an imaging biomarker to aid in the diagnosis of PCC.